InnoPharma, Inc. announced that it has closed on a $20 million term loan facility, provided by Athyrium Capital Management through its Athyrium Opportunities Fund. Proceeds will support the company's ongoing development of complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. Armentum Partners acted as financial advisors to InnoPharma for this transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.1 TWD | +20.89% | +19.00% | +9.77% |
Apr. 19 | InnoPharmax Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | InnoPharmax Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+9.77% | 46.15M | |
+15.37% | 41.97B | |
+22.56% | 22.34B | |
+14.89% | 15.25B | |
+16.53% | 14B | |
+49.78% | 12.06B | |
-10.77% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B |
- Stock Market
- Equities
- 4172 Stock
- News InnoPharmax Inc.
- InnoPharma Inc. Completes $20 Million Term Loan Facility